Carnick & Kubik’s Gilead Sciences GILD Stock Holding History

Carnick & Kubik’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-9,003	Closed	-$1.05M	–	416
2015 Q2	$1.05M	Buy	9,003 +305	+4%	+$33.3K	0.86%	43
2015 Q1	$854K	Buy	8,698 +1,135	+15%	+$115K	0.71%	54
2014 Q4	$713K	Buy	7,563 +123	+2%	+$12.7K	0.61%	58
2014 Q3	$792K	Sell	7,440 -3,020	-29%	-$296K	0.73%	50
2014 Q2	$867K	Buy	+10,460	New	+$814K	0.86%	37
2013 Q4	–	Sell	-9,605	Closed	-$604K	–	157
2013 Q3	$604K	Buy	+9,605	New	+$574K	0.92%	43

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Carnick & Kubik's GILD Position: Q3 2015 in Review

Carnick & Kubik sold out of Gilead Sciences (GILD) in Q3 2015, closing a stake of 9,003 shares — an estimated $1.05M sold.

Carnick & Kubik first reported a position in GILD in Q3 2013 and held it in 6 quarters. The position peaked at $1.05M in Q2 2015. 1,572 funds tracked by Wall St. Rank hold GILD as of Q3 2015.

Carnick & Kubik reported no remaining Gilead Sciences position as of Q3 2015 after selling out during the quarter.
Carnick & Kubik sold 9,003 Gilead Sciences shares in Q3 2015, an estimated $1.05M.
Carnick & Kubik first reported a position in Gilead Sciences in Q3 2013 and held it in 6 quarters.
Carnick & Kubik's Gilead Sciences position peaked at $1.05M in Q2 2015.
1,572 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2015.

Based on Carnick & Kubik's 13F filing for Q3 2015, filed 13 Nov 2015.